News
Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...
Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...
Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...
Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...
CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...
Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...
9don MSN
Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...
Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...
The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...
Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback